NASDAQ:FDMT

4d Molecular Therapeutics Stock Insider Trading

etoro logo Buy FDMT
*Your capital is at risk
$9.53
+0.260 (+2.80%)
At Close: Jun 03, 2026

4D Molecular Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 94.68. In total, the insiders bought 29.81M and sold 12.45M FDMT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
94.68
Buy 29.81M shares
Sell 12.45M shares
77% Buy Activity
Moderate Negative Correlation
Buy Signal High Confidence
Mar 25, 2026

Analysis Breakdown:

  • Strongly supported by a very high Insider Power Score of 94.68.
  • Confidence increased due to high data reliability score of 100.
  • Supported by overwhelming buy-side pressure (77% buys).

Historical Insider Trades

Date Type Person Role Amount
Jun 01, 2026
Sell
Common Stock
S-Sale
Kirn David
See Remarks
Officer 1 922
Value: $19.3K
Mar 25, 2026
Buy
Stock Option (Right to Buy)
A-Award
Kirn David
Chief Executive Officer
CEO / President 750 000
Value: $7.41M
Mar 25, 2026
Buy
Stock Option (Right to Buy)
A-Award
Bizily Scott
Chief Legal Officer
Officer 217 000
Value: $2.14M
Mar 25, 2026
Buy
Stock Option (Right to Buy)
A-Award
Simms Christopher Paul
See Remarks
Officer 219 000
Value: $2.16M
Mar 20, 2026
Buy
Restricted Stock Units
M-Exempt
Gupta Ashoo
Vp, Finance And Controller
Officer 221
Value: $2K
Mar 20, 2026
Buy
Restricted Stock Units
M-Exempt
Gupta Ashoo
Vp, Finance And Controller
Officer 865
Value: $7K
Mar 20, 2026
Buy
Common Stock
M-Exempt
Gupta Ashoo
Vp, Finance And Controller
Officer 865
Value: $7K
Mar 20, 2026
Buy
Common Stock
M-Exempt
Gupta Ashoo
Vp, Finance And Controller
Officer 221
Value: $2K
Mar 20, 2026
Sell
Common Stock
S-Sale
Gupta Ashoo
Vp, Finance And Controller
Officer 80
Value: $689
Mar 20, 2026
Sell
Common Stock
S-Sale
Gupta Ashoo
Vp, Finance And Controller
Officer 310
Value: $3K
Jan 05, 2026
Buy
Stock Option (Right to Buy)
Sblendorio Glenn
Director
Director 11 250
Value: $31.1K
Jan 05, 2026
Buy
Stock Option (Right to Buy)
A-Award
Sblendorio Glenn
Director
Director 45 000
Value: $328.5K
Dec 20, 2025
Buy
Restricted Stock Units
M-Exempt
Gupta Ashoo
Vp, Finance And Controller
Officer 220
Value: $2K
Dec 20, 2025
Buy
Restricted Stock Units
M-Exempt
Gupta Ashoo
Vp, Finance And Controller
Officer 866
Value: $8K
Dec 20, 2025
Buy
Common Stock
M-Exempt
Gupta Ashoo
Vp, Finance And Controller
Officer 866
Value: $8K
Dec 20, 2025
Buy
Common Stock
M-Exempt
Gupta Ashoo
Vp, Finance And Controller
Officer 220
Value: $2K
Dec 20, 2025
Sell
Common Stock
S-Sale
Gupta Ashoo
Vp, Finance And Controller
Officer 79
Value: $686
Dec 20, 2025
Sell
Common Stock
S-Sale
Gupta Ashoo
Vp, Finance And Controller
Officer 310
Value: $3K
Dec 16, 2025
Buy
Common Stock
M-Exempt
Bizily Scott
Chief Legal Officer
Officer 1 635
Value: $7K
Dec 16, 2025
Buy
Stock Option (Right to Buy)
M-Exempt
Bizily Scott
Chief Legal Officer
Officer 1 635
Value: $7K
Dec 16, 2025
Sell
Common Stock
S-Sale
Bizily Scott
Chief Legal Officer
Officer 1 635
Value: $17.8K
Dec 12, 2025
Buy
Common Stock
M-Exempt
Theuer Charles
Director
Director 9 333
Value: $10.6K
Dec 12, 2025
Buy
Stock Option (Right to Buy)
M-Exempt
Theuer Charles
Director
Director 9 333
Value: $10.6K
Dec 09, 2025
Buy
Stock Option (Right to Buy)
Simms Christopher Paul
See Remarks
Officer 32 403
Value: $134.1K
Dec 09, 2025
Buy
Stock Option (Right to Buy)
Simms Christopher Paul
See Remarks
Officer 300 000
Value: $2.81M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT 4D MOLECULAR THERAPEUTICS, INC.
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE